Data Year:

For its 2024 fiscal year, WEST PHARMACEUTICAL SVSC INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In MFG Durable industry
Eric M. Green
President and CEO, Chair of Board
Total Compensation $8,386,952 View details Pay Rank By Title In MFG Durable industry #238 View more
Annette F. Favorite
SVP, Chief Human Resources Officer
Total Compensation $1,246,060 View details Pay Rank By Title In MFG Durable industry #33 View more
Silji Abraham
SVP, Chief Technology Officer
Total Compensation $1,384,984 View details Pay Rank By Title In MFG Durable industry #42 View more
Bernard J. Birkett
SVP, Chief Financial Officer
Total Compensation $3,137,579 View details Pay Rank By Title In MFG Durable industry #219 View more
Kimberly B. MacKay
SVP, General Counsel and Secretary
Total Compensation $1,234,050 View details Pay Rank By Title In MFG Durable industry #157 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at WEST PHARMACEUTICAL SVSC INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. WEST PHARMACEUTICAL SVSC INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. WEST PHARMACEUTICAL SVSC INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Eric M. Green
President and CEO, Chair of Board
Total Cash $1,465,386 Equity $6,800,291 Other $121,275 $8,386,952
Annette F. Favorite
SVP, Chief Human Resources Officer
Total Cash $505,977 Equity $700,282 Other $39,801 $1,246,060
Silji Abraham
SVP, Chief Technology Officer
Total Cash $539,231 Equity $800,372 Other $45,381 $1,384,984
Bernard J. Birkett
SVP, Chief Financial Officer
Total Cash $825,247 Equity $2,250,252 Other $62,080 $3,137,579
Kimberly B. MacKay
SVP, General Counsel and Secretary
Total Cash $542,821 Equity $650,344 Other $40,885 $1,234,050
For its 2024 fiscal year, WEST PHARMACEUTICAL SVSC INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Eric M. Green CEO Pay $8,394,201 Median Employee Pay $61,069 CEO Pay Ratio 137:1
For its 2024 fiscal year, WEST PHARMACEUTICAL SVSC INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Deborah L. V. Keller Total Cash $342,347
Douglas A. Michels Total Cash $364,531
Janet B. Haugen Total Cash $87,620
Mark A. Buthman Total Cash $376,944
Molly E. Joseph Total Cash $331,782
Myla P. Lai-Goldman Total Cash $359,252
Paolo Pucci Total Cash $367,583
Robert F. Friel Total Cash $342,653
Stephen H. Lockhart Total Cash $331,347
Thomas W. Hofmann Total Cash $389,041
William F. Feehery Total Cash $358,660
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.